These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
7. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A Molecules; 2020 May; 25(11):. PubMed ID: 32485894 [TBL] [Abstract][Full Text] [Related]
8. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection. Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606 [TBL] [Abstract][Full Text] [Related]
9. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. Das S; Sarmah S; Lyndem S; Singha Roy A J Biomol Struct Dyn; 2021 Jun; 39(9):3347-3357. PubMed ID: 32362245 [TBL] [Abstract][Full Text] [Related]
11. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target. Arun KG; Sharanya CS; Abhithaj J; Francis D; Sadasivan C J Biomol Struct Dyn; 2021 Aug; 39(13):4647-4658. PubMed ID: 32571168 [TBL] [Abstract][Full Text] [Related]
12. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach. Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467 [TBL] [Abstract][Full Text] [Related]
13. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation. Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995 [TBL] [Abstract][Full Text] [Related]
14. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315 [TBL] [Abstract][Full Text] [Related]
15. Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery. Arunkumar M; Gunaseelan S; Kubendran Aravind M; Mohankumar V; Anupam P; Harikrishnan M; Siva A; Ashokkumar B; Varalakshmi P J Biomol Struct Dyn; 2022; 40(19):8961-8988. PubMed ID: 34014150 [TBL] [Abstract][Full Text] [Related]
16. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2. Al-Khafaji K; Al-Duhaidahawi D; Taskin Tok T J Biomol Struct Dyn; 2021 Jun; 39(9):3387-3395. PubMed ID: 32364041 [TBL] [Abstract][Full Text] [Related]
17. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an Majumder R; Mandal M J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of multiple SARS-CoV-2 proteins by an antiviral biomolecule, seselin from Nivetha R; Bhuvaragavan S; Muthu Kumar T; Ramanathan K; Janarthanan S J Biomol Struct Dyn; 2022; 40(21):11070-11081. PubMed ID: 34431451 [TBL] [Abstract][Full Text] [Related]
19. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease. Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685 [TBL] [Abstract][Full Text] [Related]
20. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation. Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]